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Abstract
Introduction Antimicrobial resistance (AMR) is a growing
problem globally especially in Sub-Saharan Africa including
Kenya. Without any intervention, lower/middle-income
countries (LMICs) will be most affected due to already
higher AMR levels compared with higher income countries
and due to the far higher burden of diseases in the LMICs.
Studies have consistently shown that inappropriate use
of antimicrobials is the major driver of AMR. To address
this challenge, hospitals are now implementing antibiotic
stewardship programmes (ASPs), which have been shown
to achieve reduced antibiotic usage, to decrease the
prevalence of resistance and lead to significant economic
benefits. However, the implementation of the guideline is
highly dependent on the settings in which they are rolled
out. This study, employing an implementation science
approach, aims to address the knowledge gap in this area
and provide critical data as well as practical experiences
when using antibiotic guidelines and stewardship
programmes in the public health sector. This will provide
evidence of ASP performance and potentially contribute
to the county, national and regional policies on antibiotics
use.
Methods and analysis The study will be conducted in
three geographically diverse regions, each represented
by two hospitals. A baseline study on antibiotic usage,
resistance and de-escalation, duration of hospital stay,
rates of readmission and costs will be carried out in the
preimplementation phase. The intervention, that is, the
use of antibiotic guidelines and ASPs will be instituted for
18 months using a stepwise implementation strategy that
will facilitate learning and continuous improvement of
stewardship activities and updating of guidelines to reflect
the evolving antibiotic needs.
Ethics and dissemination Approvals to carry out the
study have been obtained from the National Commission
for Science, Technology and Innovation and the Mount
Kenya University Ethics Review Committee. The approvals
from the two institutions were used to obtain permission
to conduct the study at each of the participating hospitals.
Study findings will be presented to policy stakeholders
and published in peer-reviewed scientific journals. It is
anticipated that the findings will inform the appropriate
antibiotic use guidelines within our local context.

Strengths and limitations of this study
►► First study aimed at concurrently rolling out antimi-

crobial stewardship committees in multiple hospitals in Kenya.
►► Use of implementation approach to support implementation of suggested guidelines for antimicrobial
resistance surveillance.
►► First-hand evidence on the antimicrobial resistance
in three diverse counties in Kenya.
►► The study is limited to only 3 of the 47 counties in
Kenya.

Introduction
Antibiotic resistance is a serious public health
concern globally1 2 and locally3 4 and fears of
running out of antibiotic options in the near
future have been expressed. In 2016, WHO
called for immediate and concerted efforts
to mitigate this threat to global health, which
was estimated to contribute to 700 000 deaths
in 2014 and projected to cause 10 million
deaths in 2050, if inadequately mitigated.5
The driving force escalating rates of resistance is the injudicious use of antibiotics in
patients, in livestock and in agriculture, and
its unchecked release into the environment.6
These forces raise and increase the spread
of resistant pathogens that may emerge by
mutations or acquisition of plasmids carrying
resistance genes.7 In one study, prior antibiotic exposure was the key independent risk
factor for the acquisition of antibiotic multiresistance.8 Broad-spectrum antibiotics have
the unintended consequence of selecting
multidrug-resistant pathogens and increasing
the likelihood of infection by fungi and Clostridium difficile.9
The injudicious use of antibiotics is widespread. In Africa, many patients do not receive
treatment from the conventional healthcare
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Justification
Antibiotic resistance is a major health challenge globally.
Studies in Kenya have shown rising antibiotic resistance
over the last three decades. While antibiotic guidelines
and ASPs have been observed to lead to significant
economic benefits, reduce antibiotic usage and lower
the prevalence of resistance especially in Europe, North
America, Japan and South Africa, they have not been
employed to tackle the challenge in the public health
sector in Kenya. The GARP report of 2011 recognised
the use of guidelines and stewardship programmes as a
potential strategy in ‘saving antibiotics’ but noted the
need for local studies to understand implementation
challenges, derive lessons and embed the strategy within
the Kenyan healthcare system. The here proposed study,
employing an implementation science approach, aims to
address the knowledge and research gap in this area and
provide critical data and experiences in using antibiotic
guidelines and stewardship programmes in the public
health sector.
2

Objectives of the study
General objectives
The overall aim is to evaluate the impact of antibiotic
guidelines for empirical treatment of (1) urinary tract
infections, (2) community-
acquired pneumonia, (3)
bacteraemia and (4) meningitis in terms of reducing
usage of broad-spectrum antibiotics, antibiotic de-escalation, duration of hospital stays, rates of readmission and
prevalence of antibiotic resistance in six county hospitals
in Kenya.
Specific objectives
1. To develop guidelines for antibiotic use for common
infections.
2. To set up antibiotic steward committees (ASCs) in six
county hospitals.
3. To train the ASC members such that they can fully perform their mandate.
4. To measure the usage of broad-spectrum antibiotics,
antibiotic de-escalation, duration of hospital stays and
rates of readmission in hospitals using the antibiotic
stewardship strategy.
5. To ascertain antibiotic resistance patterns using culture, sensitivity and genetic markers.
6. To establish the knowledge of healthcare workers,
their attitudes and prescription practices regarding antibiotics resistance, use of guidelines and ASPs.
7. To evaluate the economic benefits of using guidelines
for antibiotics use and ASPs.
Expected outputs of the research
1. Antibiotic guidelines informed by local bacteria susceptibility patterns.
2. ASCs in six county hospitals in Kenya.
3. Trained ASC members.
4. Data on antibiotics usage, antibiotic de-escalation, duration of hospital stay and rates of readmission in hospitals using the antibiotic stewardship strategy.
5. Map and data of antibiotic resistance patterns before
and after implementation of the strategy.
6. Qualitative data on the knowledge of healthcare workers, their attitudes and practices regarding antibiotic
usage and stewardship programmes.
7. Publication on cost–benefit analysis (CBA) for using
antibiotic guidelines and ASPs.
Methods and analysis
Setting
To be able to evaluate the antibiotic stewardship
strategy across Kenya using an implementation science
approach, the study will be conducted in six county
hospitals, namely (1) Kiambu County Referral Hospital,
(2) Bungoma County Hospital, (3) Webuye Sub-County
Hospital, (4) Nakuru County Teaching and Referral
Hospital, (5) Thika Level 5 Hospital and (6) Naivasha
Sub-County Hospital.
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system. Of those who receive antibiotics, 31.7% do not
consult a doctor for a prescription and a further 26.4%
obtain the antibiotics over the counter.10 A study in South
Africa found that 54.9% of antibiotics were inappropriately prescribed in intensive care unit settings while in the
USA, 20%–50% of prescribed antibiotics were unnecessary or unwarranted.11–13
The rate of antimicrobial resistance in developing countries like Kenya is worrying and rising.14 For example, the
prevalence of Salmonella typhi resistant to two or more
antimicrobials was found to have increased from 50% in
1998 to 78% in 2004 at Kenyatta National Hospital.15 The
Global Antibiotic Resistance Partnership (GARP)—Kenya
Working Group Report of 2011 identified antibiotic resistance as a key issue in Kenya and made recommendations
to curtail the spread.16 These recommendations included
the use of antibiotic guidelines that took into consideration local resistance surveillance data and enhanced
antibiotic stewardship programmes (ASPs).16 However,
these ASPs have not been instituted at county hospitals,
and key implementation data and experiences are lacking
in their roll out.
Antibiotic stewardship is defined as ‘the optimum selection, dosage, and duration of antimicrobial treatment
that yields the best clinical outcomes for the treatment
or prevention of infection with the least toxicity to the
patient and minimal impact on subsequent resistance’.17
It has the potential to lower treatment cost and realise
economic benefits to the patient, healthcare system and
the country at large.18 19 Moreover, optimising antibiotic
use by minimising exposure, fine-
tuning dosage and
reducing superfluous therapy and focusing treatment
to the likely culprit pathogens is a strategy that boosts
patient safety20 and ultimately safeguards against antibiotic resistance.21
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In the baseline and endline studies, multidisciplinary
strategies will be employed as follows
1. Knowledge of healthcare workers, attitudes and practices on antibiotic resistance, guidelines and ASP will
be studied qualitatively and quantitatively.
2. Basic science approaches, encompassing antibiotics
culture sensitivity and molecular biology-genetic markers of resistance, will be analysed.
3. Clinical patient outcomes will be studied to evaluate
the guidelines.
4. Health economics cost savings on using guidelines and
ASP will be evaluated.
Antibiotic guidelines and ASPs: development
Antibiotic guidelines will be formulated in consultation
with senior clinicians in the study hospitals taking into
account each hospital’s antimicrobial resistance patterns.
The ASP committee will comprise a hospital physician,
a microbiologist and a pharmacist. Broad-spectrum antibiotic prescriptions will be brought to the attention of
the ASP committee members. The committee members
will perform regular ward rounds, three times a week,
in the initial stages. This will be reduced to once a week
later in the project, to optimise adherence to antibiotic
guidelines. Furthermore, the guidelines will be promoted
through training sessions, provision of pocket-size guideline cards to clinicians and pharmacists, large poster
displays in the wards and through hospital and project
websites and social media.
Gitaka J, et al. BMJ Open 2020;10:e030823. doi:10.1136/bmjopen-2019-030823

Data collection
Laboratory assessment tools will be used to determine
the preparedness of the laboratories to perform antibiotic sensitivity tests (see online supplementary file 1).
The tool will assess whether the laboratories have the
equipment necessary to perform bacterial culture, identification and susceptibility testing, such as carbon dioxide
incubators, safety cabinets and refrigerators. The tool will
also determine whether the laboratories have the internationally recommended guidelines to perform susceptibility and quality assurance tests. In addition, knowledge,
attitude and practices (KAPs) about antibiotic prescription and resistance among medical practitioners will be
assessed using a KAP tool (see online supplementary file
2). The tool will target those medical practitioners, who
usually prescribe antimicrobial drugs in the hospitals and
will include the consultants, medical officers as well as
interns, clinical officers and pharmacists. The KAP tool
will also determine the guidelines that the prescribers
use to decide on the appropriate antimicrobial drug. A
health system assessment tool will be employed to gather
baseline information on the antimicrobial stewardship
activities in each hospital (see online supplementary file
3). Information on bed occupancy, antibiotic usage and
antibiotic resistance data will be collected from each of
the hospital information systems, pharmacy management
systems and laboratory reporting systems, respectively.
Antibiotic usage will be analysed in order to determine the
impact of the intervention on antibiotic usage comparing
the intervention and the control arms. Data on antibiotics issued to adult and children inpatients only will be
factored, excluding discharge and outpatient supplies.
To consistently compare antibiotic usage, the DDD
will be used and expressed per 1000 occupied bed days
(OBDs) to account for fluctuations in activity following
WHO guidelines.23 The OBDs will be obtained from the
hospital information systems.
Culture sensitivity and genetic analyses
Nasal swabs or tracheal aspirate, urine, wound swabs
and blood samples will be taken from patients who
have consented to the study for bacteriological analysis.
Samples will be subjected to standard bacteriological analysis to isolate the culprit bacteria. Bacterial species will
be confirmed by use of biochemical test and analytical
profiles index API strips (bioMérieux France). Antimicrobial susceptibility tests will be performed on isolated
bacteria as per the Kirby-Bauer method following manufacturer’s instruction. Results will be interpreted using
the Clinical and Laboratory Standards Institute tables.24
Any bacteria isolate found to be resistant to third
generation cephalosporins will be tested for production
of extended spectrum beta-lactamase (ESBL) using the
synergy disk diffusion test. Vancomycin-resistant Enterococci (VRE) will be identified using disc diffusion tests.
Methicillin-resistant Staphylococcus aureus (MRSA) will be
detected by testing isolates resistant to cefoxitin using the
E test (AB Biodisk, Solna, Sweden) on Mueller-Hinton
3
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Design
The study will use the Reach, Effectiveness, Adoption,
Implementation and Maintenance (RE-AIM) conceptual
framework. RE-AIM involves the interaction of all the five
factors and fits well with approaches that are system based.22
The study design will encompass a preimplementation
phase, a stepwise implementation phase and an endline
study to measure the changes in outcomes between the
phases. A baseline study on antibiotic usage (defined daily
doses (DDD) per 1000), antibiotic resistance (culture and
genetic markers), antibiotic de-
escalation, duration of
hospital stays, rates of readmission, prescription patterns
and cost analysis will be carried out in the preimplementation phase. The intervention, which is the use of antibiotic guidelines and ASPs, will be instituted in the 6 county
hospitals for 18 months. The stepwise implementation
phase will involve introduction of interventions as well
as monitoring and evaluation of their effectiveness, and
thereafter improving the interventions where necessary.
The strategy will facilitate learning cycles every 4–6 weeks
and continuous improvement of stewardship activities and
updating of guidelines to reflect evolving antibiotic needs
in diverse settings. During the intervention phase, challenges faced during the implementation of the guidelines
will be documented and used to advise on the changes
required during the review of the guidelines. The endline
study will be conducted and differences between the two
phases evaluated as per statistical analysis.
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CBA for the use of antibiotic guidelines and ASP
A CBA from a health facility and a national perspective will be performed. For health facilities, three cost
drivers will be considered: (1) pharmacy spending, (2)
length of stay and (3) antimicrobial stewardship interventions (training, infection control measures and so
on). At country level, we will consider disability-adjusted
life years, work-days lost and cost of treatment.25–27 This
will be done by collecting and analysing data on patient
income, length of hospital stay, death or disability occasioned by drug-resistant pathogens, hospital pharmacy
expenditure and cost of training/rolling out antimicrobial stewardship guidelines. This data will be collected
before and after antimicrobial stewardship interventions.
Study size
Prevalence of inappropriate use of broad-spectrum antibiotics
The sample size is based on the prevalence of inappropriate use of broad-spectrum antibiotics, documented as
being about 50% in South Africa.11 To detect a reduction
of the 50% inappropriate use of broad-spectrum antibiotics by 20%–30% with a power of 90% and α of 0.05 in a
two-sided test, a sample size of 410 in each county hospital
would be adequate. In order to detect a reduction (20%)
but with a power 80%, the sample size would be 320
as shown in figure 1. With a 15% allowance for loss to
follow-up, a total of about 500 participants would be sufficient in each of the selected county hospitals. Therefore,
we shall evaluate the prevalence of inappropriate use of
broad-spectrum antibiotics in 500×6= 3000 patients from
the six facilities.

Figure 1 Statistical power analysis for sample size
determination for the prevalence of inappropriate use of
broad-spectrum antibiotics.

4

Figure 2 Statistical power analysis for sample size
determination for the prevalence of antibiotics resistance.

Prevalence of antibiotic resistance
The sample size is based on the prevalence of antibiotic
resistance of 78%15 in 2004 at Kenyatta National Hospital,
Kenya. To detect a reduction of the 78% antibiotic resistance by 10%–68% with a power of 90% and α of 0.05
two-sided test, a sample size of 500 in each county hospital
would be adequate; while to achieve a reduction of 10%
with power 80%, the sample size would need to be 220
(figure 2). With 15% allowance for loss to follow-up, a
total of 600 participants would be sufficient in each of the
selected county hospitals. Therefore, we shall evaluate
the prevalence of resistance in 600×6 = 3600 patients for
the 6 facilities.
Data management
Data will be recorded on a standardised case report form
at every hospital by the trained study staff. The data will
be held locally and uploaded to the secure central study
server hosted at the Mount Kenya University main campus
in Thika. This will be overseen by the data manager/
statistician, who will run regular reconciliation to derive
the final study database. Access to the study database
will be restricted and password protected. The data will
be stored in excel, jpeg and word files for the electronic
cases. For archiving purposes, the Mount Kenya University electronic repository will be used to ensure that the
data are publicly available. Collected data will be retained
according to the policy governing the Mount Kenya
University repository. The principal investigators involved
in this study do not have any reasons that might prohibit
the sharing of the data emanating from the study.
Statistical analysis
The data will be analysed using qualitative and quantitative methods. Qualitative data will be analysed by
subjecting the information to content analysis and
presenting it in different emerging themes. The summaries of the data emanating from these themes will then
be arranged on a case-by-case basis through the use of
an Excel spreadsheet28 and the analyses performed using
Gitaka J, et al. BMJ Open 2020;10:e030823. doi:10.1136/bmjopen-2019-030823
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agar supplemented with 2% NaCl and incubated at
37°C for 24 hours. The identified ESBL, VRE and MRSA
samples will be analysed by PCR and sequencing to identify the resistance genotype. In vitro conjugation tests will
be performed to determine if resistance in bacteria is
transferable.

Open access

Ethics and dissemination
Approvals to carry out the study have been obtained from
the National Commission for Science, Technology and
Innovation (NACOSTI) (NACOSTI/P/18/33304/25986)
and the Mount Kenya University Ethics Review Committee
(MKU/ERC/0764). In addition, permission was obtained
from each of the participating hospitals. This entailed
submission of an introduction letter attaching the certificate of clearance from NACOSTI and the ethical review
certificate from MKU. In Thika, Nakuru and Naivasha, a
research fee was paid as required by the hospital board.
The study will follow all provisions of the Declaration of
Helsinki. Participants in the study will not incur any cost
associated with the transport or processing of the samples;
neither will they receive any monetary inducements to
participate in the study. Material transfer to laboratories
outside of Kenya shall not be undertaken in this study.
Informed written consent will be sought from the participants enrolled in the study.
Obtained results will be disseminated via different
streams, including research conferences and in peer-
reviewed journals. We are aiming for five publications
to be generated by the end of the study. These will
include the study protocol itself and the different aspects
emerging during in the course of the project. Contextualised guidelines on judicious use of antibiotics in
the six hospitals in Kenya will also be published in the
Ministry of Health’s website and that of the collaborating
hospitals for easy access by other health facility in and
outside Kenya. In addition, the findings will be shared
in a dissemination forum bring together members of
the health management teams at both the country and
county levels, clinicians who do prescription of antimicrobial drugs, researchers, members of the public and other
key stakeholders. The dissemination forum will be held
once at the end of the study.
Patient and public involvement
The study is mainly targeting clinicians who do antimicrobial proscription and, therefore, patients will not be
directly involved in the study. Reports obtained from this
study will, however, be made available to the patients
in the participating hospitals through a dissemination
forum and to the general public through publications.
Exit strategy and stakeholder involvement
In the process of developing this protocol, we have
engaged physicians working in the proposed county
Gitaka J, et al. BMJ Open 2020;10:e030823. doi:10.1136/bmjopen-2019-030823

hospitals, and they have identified the challenge of antibiotic resistance as real and appreciate the opportunities
that use of antibiotic guidelines and ASPs may provide in
combating resistance, improving clinical care and saving
costs. We plan to continue involving all the stakeholders
in the process, including clinicians, laboratory personnel,
pharmacists, public health officials, patients and scientists.
We anticipate that the study findings will inform county
and national policy on mitigating antibiotic resistance
and raise public awareness on the need for judicious use
of antibiotics. The project will use social media platforms,
websites of the collaborating institutions and publications
in peer-reviewed journals, local dailies and presentations
in scientific meetings to further engage stakeholders
and the public on this important issue and enhance the
learning approach inherent in the strategy of implementation science for improved performance of the ASPs and
the study in general. In case any of the hospitals dropout
either during the baseline phase or early stages of the
implementation phase, another hospital will be brought
onboard. Replacements will not be considered during the
late stages of the project.
Discussion
The emergence of antimicrobial-resistant pathogens and
a lack of new drugs to effectively treat these pathogens are
the two main challenges in human health. There is thus
the need to advocate the proper use of the currently available antimicrobial agents by safeguarding their effectiveness. Antibiotic stewardship has been shown to contribute
to reducing antibiotic resistance,29 30 but this strategy has
not been rolled out in most sub-Saharan countries in
level 4 and 5 hospitals. The proposed work will employ
an implementation research approach to evaluate the
best strategies and derive lessons on mainstreaming antibiotic stewardship in these facilities. By leveraging on a
health system approach, the implementation research
will unravel real-life impediments and opportunities by
working with hospital teams to codesign execution plans,
monitor and evaluate and the sustainability of the stewardship programmes.
Most hospitals in Kenya lack the capacity to carry out
antimicrobial sensitivity tests, due to the lack of resources
and technical knowhow, among other challenges.31 This
study will first provide an assessment to determine the
challenges hospitals are facing; this will be done through
interviews with clinicians and assessment of the capacity
of the laboratories to perform the sensitivity tests. These
steps will make up the initial phase and will guide the
nature of implementations to be used during the implementation phase. It is hoped that the project will capacitate the laboratories in the six hospitals to do the tests
and sensitise the clinicians on the need to prescribe antimicrobial drugs based on results obtained from the laboratory tests. After the implementation phase, the endline
phase will involve surveys similar to those conducted
during the baseline phase. This will allow determination
5
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NVivo software. Quantitative data analyses will be carried
out using Stata V.14 (Stata). The differences between
baseline and endline on all the study outcomes will be
compared using appropriate statistical methods, such as
McNemar’s test, paired t-test and the Wilcoxon signed-
rank test (non-parametric test), accounting for pairing
and clusters (hospitals). Multivariable log-
binomial
regression analysis will be used to elucidate risk factors
for antibiotic resistance.
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2019
Activity

Q1

2020
Q2

Q3

Q4

Q1

2021
Q2

Q3

Q4

Q1

Q2

Q3

Q4

Ethics clearance and authorisation from
study sites
Baseline study on prevalence of antibiotic
resistance and stewardship activities
Identification of members for the antibiotic
stewardship programmes (ASPs)
Development of antibiotic guidelines
Adopting and preparing materials for ASP
training
Development of antibiotic guidelines and
stewardship mobile application
Training the ASP members
Collecting data on antibiotic usage in the
hospitals
Conducting KAPs study on use of guidelines
and ASPs
Analyse and present antibiotic resistance
data using maps and charts
Presenting findings to stakeholders and
preparing the final report
KAP, knowledge, attitude and practices.

of the impact of the implementation strategies taken in
reducing the cost of treatment, length of hospital stay and
burden on the health system, among others.
The hospital management teams play a key role in
determining the allocation of resources to and within the
hospitals.32 In this project, we have proposed to involve
hospital management by including its members in the
stewardship committees that will be established. This will
ensure that the management is well informed about the
challenges in the sections involved in surveillance and the
progress that is being made. Involvement of the hospital
management will also ensure that there is a buy-in of the
recommendations made by the stewardship committee.
Although there is the need to establish antimicrobial
stewardship committees in all the hospitals, the project
proposes to start with the selected six hospitals with the
hope that the same can be reproduced by other hospitals
to establish similar committees in their hospitals.
Study timeline
year period. Enrolment
The study is designed for a 3-
already started in 2018 and participant recruitment will
continue up to 2020 (table 1). So far, stewardship committees have been established and workshops to sensitise the
members conducted. Data collection on KAP of antibiotic prescribers in the hospitals is already in progress.
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